Background:
Introduction
Neuroblastoma is the most frequent extracranial solid tumor in children accounting for 8-10% of all childhood cancers and for 15% of pediatric oncology deaths 1 . A major hallmark of the disease is its broad variety of clinical behavior ranging from spontaneous regression or maturation of disease to fatal tumor progression despite intensive multimodal treatment. To appropriately tailor therapy current trials use different combinations of clinical and genetic markers to discriminate patients with low-, intermediate-, and high-risk of death from disease.
These markers include age at diagnosis 2 , tumor stage 3, 4 , genomic amplification of the MYCN proto-oncogene (MNA) 5, 6 , deletion or imbalance of chromosome 1p (del1p) and chromosome 11q (del11q) 7, 8 , DNA ploidy 9 and a histopathologic classification system proposed by Shimada 10 . Yet, despite elaborate risk estimation systems, stratification is still imperfect resulting in over-or undertreatment of neuroblastoma patients.
In recent years, several well-conducted studies demonstrated that molecular classification using mRNA expression information more accurately reflects the individual tumor behavior at the time of diagnosis than traditional clinical markers and might therefore allow for improved risk stratification and therapy selection [11] [12] [13] [14] [15] [16] [17] . However, to date, none of the published gene-expression based classifiers has been incorporated into clinical classification systems or validated prospectively in a controlled trial. The reasons for this insufficient transfer of promising basic research findings into clinical applications are diverse and comprise high logistic and bureaucratic efforts to implement genomic classifiers into clinical practice, difficulties to setup randomized controlled trials for relatively small patient numbers and the challenge to appropriately adjust cytotoxic dosing according to binary genomic classification results. At present, it is therefore still unclear if genomic classification approaches will eventually lead to improved treatment concepts and outcome of neuroblastoma patients.
To overcome this limitation, we here report on the generation of a novel gene expression-based classifier that accurately classified patients in a comprehensive neuroblastoma cohort of internationally collected specimens. We determined subgroups of
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Author Manuscript Published OnlineFirst on September 17, 2014; DOI: 10.1158/1078-0432.CCR- patients for whom genomic classification using our predictor might offer the biggest clinical benefit. Finally, we describe in detail how our genomic classification model can be integrated into a revised risk stratification system as a therapy stratifying marker that allows for an improved determination of the intensity of frontline therapy in newly diagnosed non-high risk neuroblastoma patients.
Research. 
Material and Methods

Patients
This study comprised 709 newly diagnosed neuroblastoma patients from nine centers in nine countries for whom pre-treatment tumor material was available: Belgium (n=5, 0.7%); France (n=19, 2.7%); Germany (n=517, 72.9%); Israel (n=12, 1.7%); Italy (n=24, 3.4%); Japan (n=20, 2.8%); Spain (n=14, 2.0%); United Kingdom (n=5, 0.7%) and the United States (n=93, 13.1%).
All patients were registered in the respective clinical trials with informed consent. Patients' age at diagnosis ranged from 0 to 305 months (median age, 14.2 months). Median follow-up for patients without fatal events was 6.7 years (range, 0 to 19 years). Five-year event-free survival (EFS) of the total cohort was 0.64±0.02, and 5-year overall survival (OS) was 0.78±0.02. Data on EFS were available for 688 and data on OS were available for all 709 patients. 
Gene Expression Analyses and Supervised Classification
Generation of gene-expression profiles: Single-color gene-expression profiles were generated using customized 4x44K oligonucleotide microarrays produced by Agilent Technologies (Palo Alto, CA, USA). Labeling and hybridization was performed as described 19 . After washing and scanning, resulting TIFF-images were processed using Agilent's Feature Extraction software Version 9.5.1. Both the raw and the processed expression profiling data and basic clinical Data pre-processing: raw gene expression data were normalized using the quantile algorithm from limma 20 . In order to maintain the comparable scale of the training and validation data set, the validation set was pre-processed using the training data set as a reference. All calculations were performed in R v2.14.1 21 . Subsequently, gene-expression based classifiers were generated.
Classifier training and evaluation: The classifiers were trained using recursive feature elimination method for feature selection 22 and a linear SVM as classification algorithm. The nested cross validation (5xCV for outer loop, 3xCV for inner loop) was performed with ten repetitions. The average and the variance of classifier performance were evaluated using the following performance measures: accuracy 23 , sensitivity (SEN), specificity (SPEC), Matthew's correlation coefficient (MCC), root mean squared error and area under the curve (AUC) of a receiveroperating characteristics curve.
Feature selection: Features (i.e. microarray probes for transcripts whose expression values were considered for classification) were selected using SVM based recursive feature elimination (SVM-RFE) method 22 . The initial set of features consisted of all probes (43,291, excluding the control probes). The features were then ranked based on how frequently they have been selected in 50 cross-validation runs. The upper threshold for selecting the features for building a classifier was 65% of all cross-validation runs. This threshold was gradually lowered from 64%
to 10% in 2% increments to evaluate the classifiers' performance of the larger feature space.
The classifiers SVM_th44, SVM_th26, SVM_th24, SVM_th22, and SVM_th10 were trained on all available training data using variables that have been selected in 44%, 26%, 24%, 22% and 10% of all cross validation runs, respectively.
Statistical Analyses
Results
Generation and validation of single-color gene-expression classifiers for neuroblastoma patients
We generated more than 200 different classification models from expression profiles of a training set of 75 patients with maximally divergent courses of the disease (death from disease (UF, n=22) vs event-free survival >1000 days without cytotoxic treatment (F, n=53) ). All models were evaluated by a complete 10 times repeated 5-fold cross-validation. 
Performance of gene expression based classification in the entire validation cohort and clinical risk groups defined according to the German neuroblastoma trial NB2004
To further evaluate the performance of the five selected SVM classifiers, Kaplan-Meier analyses for EFS and OS were performed for both the complete cohort of test set patients (n=634) and for sub-cohorts of patients considered to have a low (n=313), intermediate (n=69) or high risk (n=234) of death from disease as determined by the criteria of the current German neuroblastoma trial NB2004 25, 26 . Of note, 18 patients of the total cohort could not be categorized according to these criteria because of either missing chromosomal 1p status (n=12), heterogeneous 1p status (n=3) or heterogeneous MYCN status (n=3). We here report on the In contrast, the classifier was not able to discriminate patients with divergent outcome in the two main sub-cohorts that define high risk disease 27 : (i) patients with MYCN amplified disease (n=114) and (ii) stage 4, MYCN non-amplified patients >18 months of age 2 (n=102). In the sub-cohort of MYCN amplified cases it was observed that almost all patients (113/114) were predicted as unfavorable and had a poor outcome (EFS 0.31±0.05 and OS 0.37±0.05). Only one patient who carried a MYCN amplification was predicted as favorable, and this patient has survived event-free to date (both p-values not significant; Supplementary Figure 1a) . Similarly, 2 In the German NB2004 trial, stage 4 MYCN non-amplified patients were considered high risk when older than 12 months of age. However, since an age-cut-off of 18 months excelled as a prognostic marker in recent years, we also used an 18 months cut-off in the present study, thereby leaving out 18 stage 4 patients between 12 and 18 months of age who had been stratified as high risk by the NB2004 risk estimation system 25, 26 .
Research. To furthermore visualize the contrasting transcriptomic characteristics of neuroblastoma patients with favorable and unfavorable outcome, we performed a hierarchical cluster analysis using expression data of the 194 classifying features of the SVM_th10 predictor. As shown in 
Discussion
In recent years, several studies have demonstrated that genomic classification models, in particular those based on gene expression information, more accurately predict outcome of neuroblastoma patients than conventional risk estimation systems [11] [12] [13] [14] [15] [16] [17] . In line with these reports, we here also observed that our novel SVM_th10 classifier significantly separated newly diagnosed, pre-treatment neuroblastoma patients with divergent outcome both within risk groups defined by the criteria of the current German neuroblastoma trial NB2004 and in additional clinically relevant subgroups of the disease. Intriguingly, we noticed a particular high classification performance in the large cohort of low-and intermediate-risk patients, in which our genomic classifier reliably identified patients with adverse outcome. This finding underlines the capability of gene expression information to predict aggressive tumor behavior where conventional risk stratification fails.
The high accuracy of the present classifier to discriminate non-high risk neuroblastoma patients is at least comparable to that observed in other studies, including a 144-gene PAM classifier presented by our group a few years ago 11, 13, 15, 16 . With regard to the technical differences of these two classifiers it is reassuring to note that the predictive performance of both classifiers is similar although they were generated on different versions of microarrays (previously 2x11K arrays vs 4x44K arrays in the present work) and using different experimental protocols and bioinformatics algorithms (two-color analyses vs single-color analyses; PAM vs SVM algorithm). In our minds, the observed analogue classification accuracy of both predictors not only supports the notion that classifiers built from single-or dual-color microarray experiments perform similarly well 19 but also proves the often-doubted robustness and prognostic reliability of array-based expression signatures. microarray analyses can be considered a major argument supporting the use of microarrays instead of more cost-intense and more intricate sequencing-based approaches. However, future studies are required to clarify whether RNA sequencing-based approaches, which deliver expression profiles with an unprecedented level of detail, will allow for a higher classification accuracy of neuroblastoma patients than microarray-based models.
In recent years, accumulating data indicated that treatment with reduced cytotoxic dose intensity is safely possible in neuroblastoma patients with intermediate risk of death from disease 28, 29 . In addition, it was also shown that a high percentage of infant neuroblastoma tumors undergo spontaneous regression with first signs of regression remarkably appearing beyond the first year of life in some patients 30 . This data clearly documents that the underlying tumor biology of a substantial fraction of neuroblastoma tumors is little to non-aggressive despite being considered as intermediate-risk by current markers. Together with the plausible presumption that the sum of expressed genes in a tumor reflects its biological behavior it is therefore not surprising that genomic classification approaches more reliably distinguish lowand intermediate-risk tumors with contrasting behavior as shown both by the present study and by previous reports from several other groups 11, 13, 16, 17 . 
Integration of gene-expression based classification into a revised risk estimation and therapy stratification system for non-high risk neuroblastoma patients
To eventually prove in a prospective clinical trial that our molecular classifier will inure to the benefit of those subgroups of neuroblastoma patients for which our classifier appears to offer a more accurate view of the underlying tumor behavior than current risk estimation approaches, we intend to implement the SVM_th10 classifier into a clinical protocol. Thus, we here propose to revise both risk stratification and treatment concepts of non-high risk neuroblastoma patients in the upcoming next German neuroblastoma trial as indicated in Figure 4 . This proposed revision is based on the following findings. First, the SVM_th10 classifier was able to identify patients with highly aggressive tumor biology within the cohort of patients with localized, MYCN non-amplified disease ≥18 months of age, in whom a more intensive first-line treatment appears to be justified. Therefore, we propose to consider these patients as high risk and to treat them accordingly in the upcoming German NB trial protocol (Figure 4) . Second, our data supports the hypothesis that therapy reduction might safely be possible in those patients of the same subgroup who receive a favorable gene expression-based prediction. Thus, as shown in Figure   4 , we propose that treatment of these patients shall follow either an observational approach (for stage 1 and 2 patients) or an intermediate risk therapy of reduced intensity (IRG-reduced for stage 3 patients). A similar reduction of cytotoxic dose intensity will also be assessed for stage 4, MYCN non-amplified patients <18 months of age, who receive a favorable genomic classification, while patients of this group with an unfavorable classification result will be treated with a non-reduced intermediate risk therapy. Likewise, stage 4S, MYCN non-amplified patients with unfavorable genomic classification will also receive the non-reduced intermediate risk therapy (Figure 4) . Finally, no change in the first-line therapy is intended for the small cohort of neuroblastoma patients with localized, MYCN non-amplified disease <18 months of age, who are classified as unfavorable by the SVM_th10 predictor in order to evaluate the classifier's accuracy for these patients without a potential treatment bias. However, to prevent putting them at risk, they will continue to initially follow an observational approach but will be treated opinion, this approach is supported by both the low number of events and the good overall outcome of these patients (5y-OS 0.86±0.13) as highlighted in Figure 2b .
With the proposed revision of risk stratification and treatment for non-high risk neuroblastoma patients we intend to both improve outcome of patients whose aggressive tumor behavior is not captured by current risk stratification concepts, and to safely reduce treatment in those patients who are currently considered as intermediate risk but whose molecular profile suggests non-aggressive disease. To visualize the potential benefit of our proposed approach, Figure 5 highlights the outcome of the 413 non-high risk patients of this study stratified both according to the present German NB2004 trial protocol (Figure 5a ) and according to the proposed revised approach (Figure 5b ). In total, 382 of the 413 non-high risk patients could be stratified into either low or intermediate risk of death from disease according to the current NB2004 risk stratification system. The 5-year EFS and OS for patients of the low risk group Three clinical trials by Baker et al. 28 , Rubie et al. 29 and Hero et al. 30 proved that therapy reduction in different subgroups of non-high risk patients did not result in inferior patient outcome and thus underline the feasibility of our concept to offer reduced cytotoxic dose intensity for non-high risk patients with a favorable molecular prediction. In contrast, it remains to be determined whether an intensification of cytotoxic treatment for patients whose tumors are molecularly unfavorable will result in reduced rates of relapse or death from disease.
Considering the fact that our classifier was trained to discriminate patients whose tumors have the potential to regress spontaneously (as indicated by >1000 days of EFS without chemotherapy) from those who died despite comprehensive treatment efforts it is conceivable that an unfavorable prediction may indicate tumors that are incurable despite best currently available therapy. Yet, in our proposed revised treatment protocol the therapeutic intensity will be increased for unfavorably classified patients with either localized, MYCN non-amplified disease >18 months of age (who will be treated according to the high risk protocol) or with stage 4S, MYCN non-amplified disease (who will be treated according to the standard intermediaterisk treatment protocol). The observation that due to intensified second line treatment the overall survival of these two patient subgroups was substantially better than event-free survival may argue against the hypothesis that treatment escalation will be ineffective in those sub-cohorts.
We therefore hypothesize that intensified treatment of these patients will improve event-free survival at least to the level of the overall survival (50% at 5 years) observed in this study.
Practical issues of performing RNA-based biomarker analysis for neuroblastoma patients
The implementation of our gene-expression classifier into a revised risk stratification system of a clinical trial requires consideration of some practical issues. First, the turn-around time that is required for the genomic classification result is an important aspect. In our experience, 3 working days are required to isolate RNA from fresh-frozen tumor material, to assess tumor histology and RNA quality and to perform the microarray experiments including quality control and running the classification algorithm. Thus, considering potential delays in this work-flow (e.g. adequately reflect the underlying tumor behavior. To prevent misclassifications due to tumor heterogeneity, it is intended to perform expression profiles from RNA of at least two separate parts of the tumor specimens of each patient. In case of conflictive results, it is planned to repeat the complete work flow. If the conflictive results persist, it is planned to stratify the patient according to the conventional risk classification approach. This practice may also be applicable to a small fraction of patients for whom no adequate tumor or RNA specimens can be obtained.
The latter problem, however, appears to be infrequent in low-and intermediate-risk patients.
From our experience, we expect a total dropout rate of ~5-10% of all patients due to insufficient specimen quality or heterogeneity following implementation of our molecular classifier in the upcoming neuroblastoma trial.
In conclusion, we comprehensively validated a newly built gene-expression based classifier for neuroblastoma patients using a very large cohort of neuroblastoma tumor samples.
Subsequent thorough analyses of this molecular classifier revealed that the highest clinical potential can be assumed for non-high risk patients, and indicated that the classifier distinguishes two major neuroblastoma subgroups, one with a high potential to regress or differentiate either spontaneously or after limited treatment and another with a high propensity to progress or relapse after current therapeutic concepts. Finally, we propose to evaluate the prognostic power of our molecular classifier in a clinical setting using an innovative revised risk proposed intensification of treatment intensity (n=29)). Due to a lack of proportional hazards between the curves in (a), we applied a test of proportions by comparing the point estimates for EFS and OS at 5 years after diagnosis according to the approach of Klein, et al. 37 . Thereby, we found that for EFS, the difference of 0.095 (95%-CI: -0.027; 0.236) between the two cohorts was not statistically significant (p=0.144), while we observed a difference of 0.103 (95%-CI: [0.02; Table 1a summarizes the Cox regression model based on EFS, Table 1b the model based on OS (univariate models only). The lower number of cases in the model for EFS results from a reduction of those patients for whom all variables were available (n=363). For each factor, the reference level to which the marker is compared is indicated first and underscored (e.g. "F vs. UF" for histology, "<18 months vs. ≥18 months" for age and "no aberration vs. imb/del of 1p"). Imb/del of 1p was defined according to the criteria of the European Neuroblastoma Quality Assessment Group 18 . Table 1c 
